Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Celltrion Announces Positive Two-Year Results for Zymfentra™ (Infliximab-dyyb)

May 21, 2024

On 21 May 2024, Celltrion announced positive two-year results from its extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for Zymfentra™ (infliximab-dyyb) in adults with moderately to severely active Crohn’s disease and ulcerative colitis after induction with intravenous infliximab.   Celltrion reports that the findings support the long-term efficacy and safety of Zymfentra™.

Zymfentra™ was the first subcutaneous formulation of infliximab approved by the FDA in October 2023.  Celltrion launched Zymfentra in the US in March 2024.  A formulation patent for Zymfentra was granted in the US on 9 April 2024.